Lyell Immunopharma price target raised to $10 from $1 at H.C. Wainwright

H.C. Wainwright significantly raised its price target for Lyell Immunopharma (LYEL) to $10.00 from $1.00, while maintaining a Neutral rating, following robust clinical data for its LYL314 CAR-T therapy in large B-cell lymphoma (LBCL). LYL314 demonstrated high efficacy, achieving an 88% overall response rate and 72% complete response rate in third-line patients, and a 91% ORR and 64% CRR in the challenging second-line setting, including primary refractory cases, positioning it favorably against competitors like Gilead's YESCARTA. The updated target accounts for a reverse stock split and incorporates a higher discount rate due to increasing CAR-T market competition and elevated regulatory risk from FDA personnel changes.

Analysis

H.C. Wainwright maintained a Neutral rating on Lyell Immunopharma (LYEL) while adjusting its price target to $10.00 from $1.00, an update that reflects a recent 20-for-1 reverse stock split. The action was prompted by strong new clinical data for Lyell's CAR-T therapy, LYL314, in large B-cell lymphoma (LBCL). In the third-line setting, LYL314 achieved an 88% overall response rate (ORR) and a 72% complete response rate (CRR). Performance in the more challenging second-line setting was also robust, with a 91% ORR and 64% CRR, notably among a population where 91% of patients were primary refractory. These results position LYL314 competitively against Gilead's established therapy, YESCARTA, which demonstrated an 83% ORR and 65% CRR in its second-line trial. Despite the promising clinical profile, the analyst's neutral stance is underpinned by an increased discount rate (from 9% to 10%), citing intensified competition among CAR-T products and potential for increased clinical development risk due to personnel changes at the FDA.

Key Decisions for Investors

• Investors should weigh the highly promising clinical data for LYL314, which appears competitive with Gilead's YESCARTA, against the analyst's cautious 'Neutral' rating and noted external risks.
• It is crucial to understand that the price target increase to $10.00 is a technical adjustment for a 20-for-1 reverse stock split and does not necessarily signal a bullish re-rating on a split-adjusted basis.
• Key factors to monitor include the competitive intensity within the B-cell lymphoma CAR-T market and any signs of a more stringent regulatory environment at the FDA, as these were cited as reasons for a higher discount rate.
• The stock presents a high-risk, high-reward profile where future clinical milestones and regulatory feedback will be critical catalysts for performance.